Gyne-Lotrimin

Erythrasma, Tinea Pedis, Inflammation + 37 more
Treatment
20 Active Studies for Gyne-Lotrimin

What is Gyne-Lotrimin

ClotrimazoleThe Generic name of this drug
Treatment SummaryClotrimazole is an antifungal medication used to treat fungal infections. It belongs to the imidazole class of antifungals and has a broad range of antifungal activity. It comes in several forms, including creams, pessaries, and troche formulations. It has been studied for its potential to treat sickle cell disease, malaria, and some cancers. Clotrimazole is well-tolerated and has few side effects, making it a popular treatment for yeast infections and athlete's foot.
Mycelexis the brand name
image of different drug pills on a surface
Gyne-Lotrimin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Mycelex
Clotrimazole
1983
116

Effectiveness

How Gyne-Lotrimin Affects PatientsClotrimazole is a drug used to fight fungal infections. It works by changing the cell membranes of pathogenic yeasts. At low concentrations, it stops the growth of the fungi, and at higher concentrations, it can kill them. In the past, resistance to clotrimazole was rare, however it is now more common. Clotrimazole is usually a fungistatic drug but has fungicidal properties at higher concentrations.
How Gyne-Lotrimin works in the bodyClotrimazole works by disrupting the cell membrane of fungi, which stops them from growing. It does this by blocking the production of ergosterol, a hormone-like molecule which helps the cell build and maintain its membrane. Clotrimazole also has other effects on fungi, such as blocking calcium-dependent potassium channels and voltage-dependent calcium channels, and depleting intracellular calcium. These effects are separate from its anti-fungal properties.

When to interrupt dosage

The measure of Gyne-Lotrimin is contingent upon the recognized affliction, including Vulvitis, Trichophytosis and Radiotherapy Side Effects. The dosage varies as per the technique of implementation (e.g. Cream or Topical) presented in the table beneath.
Condition
Dosage
Administration
Oropharyngeal Candidiasis
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Tinea
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Epidermophyton floccosum
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Communicable Diseases
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Candidiasis, Vulvovaginal
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Bacterial Infections
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Malassezia
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Fungal ear infection
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Trichomonas Vaginitis
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Vulvitis
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Vaginitis
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Radiotherapy Side Effects
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Tinea
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Genital candidiasis
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Cellulitis
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
symptomatic Tinea Corporis caused by Trichophyton mentagrophytes, Trichophyton rubrum, Epidermophyton floccosum
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Tinea cruris
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Ringworm
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Mixed Vaginal Infections
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical
Chemotherapy Effects
0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg
, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Warnings

Gyne-Lotrimin Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Clotrimazole may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Clotrimazole may interact with Pulse Frequency
There are 20 known major drug interactions with Gyne-Lotrimin.
Common Gyne-Lotrimin Drug Interactions
Drug Name
Risk Level
Description
Capmatinib
Major
The serum concentration of Capmatinib can be decreased when it is combined with Clotrimazole.
Rimegepant
Major
The metabolism of Rimegepant can be increased when combined with Clotrimazole.
(R)-warfarin
Moderate
The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Clotrimazole.
(S)-Warfarin
Moderate
The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Clotrimazole.
4-hydroxycoumarin
Moderate
The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Clotrimazole.
Gyne-Lotrimin Toxicity & Overdose RiskClotrimazole is unlikely to cause poisoning when used topically or accidentally ingested. There is no specific antidote for overdose. Animal studies have not revealed any effects on fertility, though limited data exists on its use in pregnant women. Clotrimazole and its metabolites are excreted in breast milk so it should not be used while breastfeeding.

Gyne-Lotrimin Novel Uses: Which Conditions Have a Clinical Trial Featuring Gyne-Lotrimin?

293 active studies are currently examining the potential of Gyne-Lotrimin in providing relief for Atopic Dermatitis, Tinea inguinalis and Balanitis candida.
Condition
Clinical Trials
Trial Phases
Tinea Versicolor
0 Actively Recruiting
Balanitis candida
0 Actively Recruiting
Mixed Vaginal Infections
0 Actively Recruiting
Skin Diseases
0 Actively Recruiting
symptomatic Tinea Corporis caused by Trichophyton mentagrophytes, Trichophyton rubrum, Epidermophyton floccosum
0 Actively Recruiting
Tinea cruris
0 Actively Recruiting
cutaneous candidiasis
0 Actively Recruiting
Yeast Infection
0 Actively Recruiting
Oropharyngeal Candidiasis
0 Actively Recruiting
Tinea cruris
0 Actively Recruiting
Candidiasis, Vulvovaginal
0 Actively Recruiting
Skin candida
0 Actively Recruiting
Epidermophyton floccosum
0 Actively Recruiting
Malassezia
0 Actively Recruiting
Inflammation
58 Actively Recruiting
Not Applicable, Early Phase 1, Phase 1, Phase 2, Phase 3, Phase 4
Cellulitis
0 Actively Recruiting
Steroids
0 Actively Recruiting
Radiotherapy Side Effects
2 Actively Recruiting
Phase 2, Not Applicable
Candidiasis, Vulvovaginal
0 Actively Recruiting
Tinea Pedis
0 Actively Recruiting

Gyne-Lotrimin Reviews: What are patients saying about Gyne-Lotrimin?

4.7Patient Review
1/16/2013
Gyne-Lotrimin for Yeast Infection of Vagina and Vulva
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about gyne-lotrimin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Lotrimin the same as Monistat?

"Gyne-Lotrimin and Monistat contain chemical compounds that set them apart from other over-the-counter treatments for yeast infections that contain natural ingredients. These homeopathic products have been available for a while, but women with severe symptoms often needed a prescription product."

Answered by AI

Is Gyne-Lotrimin over-the-counter?

"Gyne-Lotrimin is a vaginal cream that is used to treat yeast infections. It is available over-the-counter and in generic versions."

Answered by AI

Do I need a prescription for Gyne-Lotrimin?

"Gyne-Lotrimin is a prescription medication that is used to treat the symptoms of fungal infections. These infections include athlete's foot, jock itch, ringworm, and yeast infections. Gyne-Lotrimin may be used by itself or with other medications."

Answered by AI

Can Lotrimin be used for female yeast infection?

"It works by preventing the growth of yeast (fungus) that causes the infection.

This medication is used to treat vaginal yeast infections. Clotrimazole reduces vaginal burning,itching, and discharge occur with this condition. This medication is an azole antifungal. Yeast (fungus) that causes the infection."

Answered by AI

Clinical Trials for Gyne-Lotrimin

Image of UConn Health in Farmington, United States.

Cognitive Remediation for Memory and Thinking Difficulties

18+
All Sexes
Farmington, CT
The goal of this clinical trial is to determine if a neuroscience-based computerized cognitive remediation ("brain training") program can treat neurocognitive dysfunction (i.e., memory or thinking difficulties) that emerges in some older adults following a viral infection. The main questions it aims to answer are: * Does computerized cognitive remediation improve cognitive performance and day-to-day functioning in older adults with postviral neurocognitive dysfunction? * Will treatment effects be maintained over time, leading to better long term cognitive outcomes? * Does the treatment lead to reductions in blood-based markers of inflammation as a potential mechanism of cognitive symptom improvement? * Can the treatment be optimized and refined based on feedback from participants to improve user (patient) experience? Researchers will compare the computerized cognitive remediation program to an active computer-based control condition (alternative computer activities) to see if the computerized cognitive remediation program works to treat postviral neurocognitive dysfunction. Participation takes approximately 43-48 hours over 7 months, with most activities (40-46 hours) completed within the first 7-8 weeks, including: * Initial intake visit: Eligibility confirmation (\~2-3 hours) * Computer activities: About 5 hours per week for \~6 weeks (total \~30 hours) completed on a computer tablet provided by the study and loaned to participants for use during the treatment phase * Weekly remote check-in meetings: \~30 minutes each during treatment * Blood draws: Two sessions (before and after treatment), \~20-30 minutes each * Three research visits: Pre-treatment, post-treatment, and 6-month follow-up (\~2-3 hours each, including assessments of cognitive, emotional, and daily functioning)
Waitlist Available
Has No Placebo
UConn HealthCutter Lindbergh, Ph.D.
Image of Department of Nutritional Sciences in Storrs, United States.

Freeze-dried Grape Powder for Healthy Aging

50 - 75
All Sexes
Storrs, CT
The purpose of this study is to investigate the effects of consuming grape powder on immune profiles in healthy middle- and older-aged individuals. Specifically, the investigators are interested in evaluating the potential effects of grapes in influencing markers of immune function, inflammation, and metabolism that are known to change with aging. Grapes contain several nutrients and antioxidant polyphenols such as resveratrol, quercetin, vitamin K and fiber, which are known to promote heart and immune health. However, the effects of grapes on altering immune profiles within the context of aging is not well understood. Therefore, this study will explore how daily grape consumption impacts certain markers of immunity in healthy middle- and older-aged adults. The main study procedures include consumption of a freeze-dried grape powder and control powder (which tastes the same but has none of the grape compounds that are being studied) mixed with water as a beverage on a daily basis for 4 weeks each. The investigators will additionally ask that participants avoid eating grapes and certain other antioxidant/grape-related foods and beverages throughout the 13-week study. Participants will additionally be asked to complete surveys about their diet, physical activity, and medical history, as well as provide blood samples and body weight measures throughout the course of the study. Participation in the study is expected to last about 6.25 hours over the course of 13 weeks and will include 7 visits.
Recruiting
Paid Trial
Department of Nutritional Sciences
Have you considered Gyne-Lotrimin clinical trials? We made a collection of clinical trials featuring Gyne-Lotrimin, we think they might fit your search criteria.Go to Trials
Image of Abcentra Investigational Site in Los Angeles, United States.

Orticumab for Heart Attack

18+
All Sexes
Los Angeles, CA
The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies
Phase 2
Recruiting
Abcentra Investigational Site (+6 Sites)Abcentra
Image of School of Public Health in Bloomington, United States.

High Salt Intake for High Blood Pressure

60 - 85
All Sexes
Bloomington, IN
Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury/impaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.
Recruiting
Has No Placebo
School of Public Health
Image of Tesla MedBed at Tampa-FL in Tampa, United States.

Biophoton Therapy for Stem Cell Proliferation

18 - 70
All Sexes
Tampa, FL
Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can increase self-grown stem cells naturally. Study Design This is a randomized, double-blinded, placebo-controlled intervention clinical study to assess the effectiveness of biophoton therapy in impacting stem cells. Approximately 46 volunteers who want to increase self-grown stem cells will participate in the study. Study Randomization The biostatistician will prepare a randomization schedule including a serial of subject numbers. A subject number will be randomly assigned to each study participant, which will assign them to either the control group or the treatment group. Other than the Informed Consent Form (ICF), all study information will be recorded by using the subject number. The Principal Investigator, study physicians, study nurse, data-entry specialists, and biostatisticians, as well as the participants, will be blinded about who received which product during the first two weeks of study participation.
Recruiting
Online Trial
Tesla MedBed at Tampa-FL (+1 Sites)James Z Liu, MD, PhD
Have you considered Gyne-Lotrimin clinical trials? We made a collection of clinical trials featuring Gyne-Lotrimin, we think they might fit your search criteria.Go to Trials
Image of Goldring Center for High Performance Sport in Toronto, Canada.

Physical Activity for Delayed Onset Muscle Soreness

18 - 35
All Sexes
Toronto, Canada
After completing novel activity or exercise we may experience exercise-induced muscle damage (EIMD), resulting in a period of reduced muscle function and delayed onset muscle soreness (DOMS). DOMS is characterized by muscle pain and tenderness that typically resolves within a week. While the precise cause of DOMS is unknown, there is growing evidence implicating damage to the connective tissue that surrounds our muscle fibers and is related to a small amount of inflammation. This inflammation is a normal part of our body's ability to recovery from injuries and may be visualized through the use of ultrasound technology. A variety of recovery techniques have been proposed that may help with the recovery of DOMS such as massage and electrical muscle stimulation, but these are not always accessible. Therefore, we are interested in investigating whether the number of daily steps can affect how you experience DOMS.
Waitlist Available
Has No Placebo
Goldring Center for High Performance Sport
Image of UCSF in San Francisco, United States.

Moisturizers for Aging

65+
All Sexes
San Francisco, CA
This is a randomized, investigator-blinded, self-controlled pilot study of the physiologic response to topical moisturizers among older adults with dry skin. The overarching hypothesis is that skin barrier decline is an important source of chronic inflammation, and that skin barrier restoration with moisturizers can reduce serum biomarkers of inflammation. The primary objective is to determine the feasibility for a larger trial, and the secondary objectives are to determine the extent to which measures of serum inflammation, skin barrier function, and the skin microbiome change in response to moisturizers. Participants will be asked to apply one of two topical moisturizers that are widely available over the counter in the US (Vaseline® 100% pure petroleum jelly or CeraVe® moisturizing cream) once daily for 4 weeks to the front of the torso, buttocks, arms, and legs. Subjects will act as their own control (i.e. they will be asked to apply the study moisturizer they are randomized to for one intervention period (4 weeks) and not to apply topical moisturizers for the other 4- week intervention period). Participants will be randomized in a 1:1:1:1 ratio to one of 4 treatment groups: i. no intervention then CeraVe; ii. CeraVe then no intervention; iii. no intervention then Vaseline; iv. Vaseline then no intervention. At each visit (baseline, week 4, and week 8), participants will undergo skin barrier testing, skin microbiome sampling, and phlebotomy to measure serum inflammatory markers.
Phase 4
Recruiting
UCSFKatrina Abuabara, MD
Have you considered Gyne-Lotrimin clinical trials? We made a collection of clinical trials featuring Gyne-Lotrimin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security